ACKR3 and non-small cell lung carcinoma: The results showed that in NSCLC BM+ patients with wild‐type and mutant ALK, the post‐operative OS and PFS, serum levels of hsa_circ_0072309, miR‐100, and ACKR3 mRNA and protein were not statistically different (p > 0.05; Figure 5), indicating that ALK mutation had no impact on our experimental findings.